The Asia Pacific Inhalation Capsules Market would witness market growth of 6.7% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific Inhalation Capsules Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $101.8 Million by 2031. The Japan market is registering a CAGR of 6% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 7.3% during (2024 - 2031).
Inhalation capsules come in various forms, including single-dose capsules and multi-dose reservoir systems. They are often used with specialized inhalation devices that help control the airflow and ensure proper dispersion of the medication. These devices may include breath-actuated mechanisms, dose counters, and other features to enhance ease of use and patient adherence. Rising technological advancements, an increase in the prevalence of respiratory diseases, rising demand for easy drug delivery methods, and the expanding utilization of inhalation therapies have all contributed to the substantial growth of the inhalation capsules market in recent years.
Additionally, increased awareness of respiratory health and disease management prompts individuals to seek appropriate treatments. Healthcare campaigns, educational programs, and advocacy efforts emphasize the importance of early detection, proper medication adherence, and lifestyle modifications. As a result, more patients are likely to opt for inhalation therapies delivered via capsules to manage their respiratory conditions effectively.
Asia-Pacific is experiencing an increase in the prevalence of chronic obstructive pulmonary disease, which is primarily attributable to smoking, air pollution, and an aging population. Countries like China, India, and Indonesia are particularly affected, as they have high levels of air pollution and a large population of smokers. Thus, the region presents lucrative growth opportunities for the market.
Based on Type, the market is segmented into Gelatin Capsules, and Hypromellose Capsules. Based on Application, the market is segmented into Asthma Treatment, COPD Management, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific Inhalation Capsules Market by Country in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $101.8 Million by 2031. The Japan market is registering a CAGR of 6% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 7.3% during (2024 - 2031).
Inhalation capsules come in various forms, including single-dose capsules and multi-dose reservoir systems. They are often used with specialized inhalation devices that help control the airflow and ensure proper dispersion of the medication. These devices may include breath-actuated mechanisms, dose counters, and other features to enhance ease of use and patient adherence. Rising technological advancements, an increase in the prevalence of respiratory diseases, rising demand for easy drug delivery methods, and the expanding utilization of inhalation therapies have all contributed to the substantial growth of the inhalation capsules market in recent years.
Additionally, increased awareness of respiratory health and disease management prompts individuals to seek appropriate treatments. Healthcare campaigns, educational programs, and advocacy efforts emphasize the importance of early detection, proper medication adherence, and lifestyle modifications. As a result, more patients are likely to opt for inhalation therapies delivered via capsules to manage their respiratory conditions effectively.
Asia-Pacific is experiencing an increase in the prevalence of chronic obstructive pulmonary disease, which is primarily attributable to smoking, air pollution, and an aging population. Countries like China, India, and Indonesia are particularly affected, as they have high levels of air pollution and a large population of smokers. Thus, the region presents lucrative growth opportunities for the market.
Based on Type, the market is segmented into Gelatin Capsules, and Hypromellose Capsules. Based on Application, the market is segmented into Asthma Treatment, COPD Management, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Australia, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Market Report Segmentation
By Type- Gelatin Capsules
- Hypromellose Capsules
- Asthma Treatment
- COPD Management
- Others
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Asia Pacific Inhalation Capsules Market by Type
Chapter 6. Asia Pacific Inhalation Capsules Market by Application
Chapter 7. Asia Pacific Inhalation Capsules Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Cipla Limited
- Novartis AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Lonza Group Ltd. (Capsugel)
- Chiesi Farmaceutici S.p.A
- Vectura Group Plc (Philip Morris International, Inc.)
- Elpen S.A.
- Healthcaps India Ltd.
- Qualicaps Co., LTD. (Roquette Freres SA)
Methodology
LOADING...
